Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR1B | P28222 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.42 |
| ▸ | CCR3 | P51677 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532963 | 0.86 | NCF1 (0.58) | HTR1DHTR1AHTR1BHRH3NCF1 | |
| SCHEMBL5528119 | 0.85 | ADAM17 (0.44) | HTR1DHTR1AHTR1BHCRTR1HCRTR2 | |
| SCHEMBL5532322 | 0.85 | SLC2A1 (0.45) | HTR1DHTR1AHTR1BHCRTR1HCRTR2 | |
| SCHEMBL5537578 | 0.84 | HTR1A (0.53) | HTR1DHTR1AHTR1BHRH3NCF1 | |
| SCHEMBL5527371 | 0.84 | HTR1D (0.49) | HTR1DHTR1AHTR1BHCRTR1HCRTR2 | |
| SCHEMBL5528217 | 0.84 | HRH3 (0.52) | HTR1AHCRTR1HCRTR2HRH3NCF1 | |
| SCHEMBL14437441 | 0.82 | NCF1 (0.51) | HTR1DHTR1AHTR1BTLR9TLR8 | |
| SCHEMBL5529815 | 0.82 | NCF1 (0.51) | HTR1DHTR1AHTR1BNCF1 | |
| SCHEMBL14437442 | 0.82 | SCN9A (0.51) | HTR1DHTR1AHTR1BNCF1LMNA | |
| SCHEMBL5532956 | 0.81 | MCHR1 (0.53) | HTR1DHTR1AHTR1BHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197509-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | HTR1D 1094/4885HTR1A 721/4885HTR1B 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.